An adaptive phase II/III safety and efficacy randomized controlled trial of single day or three-day fixed-dose albendazole-ivermectin co-formulation versus albendazole for the trea...

Autores: Krolewiecki, Alejandro Javier; Enbiale, Wendemagegn; Gandasegui, Javier; van Lieshout, Lisette; Kepha, Stella; Messa Junior, Augusto; Bengtson, Michel; Gelaye, Woyneshet; Escola, Valdemiro; Martinez Valladares, María; Cambra Pellejà, María; Algorta, Jaime; Martí Soler, Helena; Fleitas, Pedro; Ballester, Maria Rosa; Doyle, Stephen R.; Williams, Nana Aba; Legarda, Almudena; Mandomando, Inacio; Mwandawiro, Charles; Muñoz, José
Año de publicación: 2022
Idioma: inglés
Tipo de recurso: artículo
Estado: versión publicada
Descripción: Background: Soil-transmitted helminths (STH) are targeted for control through mass drug-administration campaigns to prevent morbidity affecting at-risk groups in endemic regions. Although broadly successful, the use of albendazole and mebendazole achieved variable progress, with deficiencies against Trichuris trichiura and a predictable low efficacy against Strongyloides stercoralis. Novel drug combinations offer a potential solution, providing they can be delivered safely and maintain efficacy against all STH species. Here we present the protocol of a clinical trial to evaluate a fixed-dose combination (FDC) tablet containing albendazole and ivermectin that will be compared against albendazole against STH. Methods: An adaptive phase II/III randomized controlled trial will be undertaken in STH endemic sites in Ethiopia, Kenya and Mozambique to evaluate an oral FDC of 400 mg albendazole and either 9- or 18 mg ivermectin. FDC will be administered as a single dose or single doses over three-consecutive days and assessed against a single dose of 400 mg albendazole. In the phase II trial, 126 T. trichiura-infected children weighting 15 to 45 kg will be treated in a dose-escalation manner to determine safety objectives. In the phase III trial, 1097 participants aged 5 to 18 years old infected with T. trichiura, hookworm and S. stercoralis will be recruited to determine safety and efficacy. The trial will be open-label with blinded outcome assessors. Cure rate measured 21-days after-treatment in duplicate Kato-Katz is the primary efficacy outcome. Secondary objectives include efficacy evaluation by quantitative polymerase chain reaction (PCR) as an outcome measurement, description of pharmacokinetic parameters, palatability and acceptability evaluations, and monitoring of anthelmintic resistance. Conclusions: This trial with registrational goals seeks to evaluate an innovative fixed-dose combination of albendazole and ivermectin co-formulated tablets, with the goal of providing an anthelmintic regimen with improved efficacy and spectrum of coverage against STH. ClinicalTrials.gov registration: NCT05124691 (18/11/2021).
Fil: Krolewiecki, Alejandro Javier. Universidad de Barcelona; España. Universidad Nacional de Salta. Sede Regional Orán. Instituto de Investigación de Enfermedades Tropicales; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Enbiale, Wendemagegn. Bahir Dar University; Etiopía. Amsterdam Institute for Infection and Immunity; Países Bajos
Fil: Gandasegui, Javier. Universidad de Barcelona; España
Fil: van Lieshout, Lisette. Leiden University; Países Bajos
Fil: Kepha, Stella. Kenya Medical Research Institute; Kenia
Fil: Messa Junior, Augusto. Centro de Investigação em Saúde de Manhiça; Mozambique
Fil: Bengtson, Michel. Leiden University. Leiden University Medical Center.; Países Bajos
Fil: Gelaye, Woyneshet. Bahir Dar University; Etiopía
Fil: Escola, Valdemiro. Centro de Investigação em Saúde de Manhiça; Mozambique
Fil: Martinez Valladares, María. Universidad de León; España. Consejo Superior de Investigaciones Científicas; España
Fil: Cambra Pellejà, María. Universidad de León; España. Consejo Superior de Investigaciones Científicas; España
Fil: Algorta, Jaime. Liconsa Sa; España
Fil: Martí Soler, Helena. Universidad de Barcelona; España. Consejo Superior de Investigaciones Científicas; España
Fil: Fleitas, Pedro. Consejo Superior de Investigaciones Científicas; España. Universidad de Barcelona; España
Fil: Ballester, Maria Rosa. Centro de Investigación Biomédica en Red de Salud Mental; España. Institut d’Investigació Biomèdica Sant Pau; España
Fil: Doyle, Stephen R.. Wellcome Sanger Institute; Reino Unido
Fil: Williams, Nana Aba. Universidad de Barcelona; España. Consejo Superior de Investigaciones Científicas; España
Fil: Legarda, Almudena. Consejo Superior de Investigaciones Científicas; España. Universidad de Barcelona; España
Fil: Mandomando, Inacio. Centro de Investigação Em Saúde de Manhiça; Mozambique
Fil: Mwandawiro, Charles. Eastern and Southern Africa Centre of International Parasite Control; Kenia
Fil: Muñoz, José. Universidad de Barcelona; España. Consejo Superior de Investigaciones Científicas; España
Materia: ANTIHELMINTICS
STH
TRICHURIS TRICHIURA
HOOKWORM
ALBENDAZOLE
IVERMECTIN
Nivel de accesibilidad: acceso abierto
Condiciones de uso: https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
Institución: Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador: oai:ri.conicet.gov.ar:11336/244741

Acceder

id	CONICETDig_086c2a7445a0f1747cde8d7f66bd928d
oai_identifier_str	oai:ri.conicet.gov.ar:11336/244741
network_acronym_str	CONICETDig
repository_id_str	3498
network_name_str	CONICET Digital (CONICET)
spelling	An adaptive phase II/III safety and efficacy randomized controlled trial of single day or three-day fixed-dose albendazole-ivermectin co-formulation versus albendazole for the treatment of Trichuris trichiura and other STH infections. ALIVE trial protocolKrolewiecki, Alejandro JavierEnbiale, WendemagegnGandasegui, Javiervan Lieshout, LisetteKepha, StellaMessa Junior, AugustoBengtson, MichelGelaye, WoyneshetEscola, ValdemiroMartinez Valladares, MaríaCambra Pellejà, MaríaAlgorta, JaimeMartí Soler, HelenaFleitas, PedroBallester, Maria RosaDoyle, Stephen R.Williams, Nana AbaLegarda, AlmudenaMandomando, InacioMwandawiro, CharlesMuñoz, JoséANTIHELMINTICSSTHTRICHURIS TRICHIURAHOOKWORMALBENDAZOLEIVERMECTINhttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3Background: Soil-transmitted helminths (STH) are targeted for control through mass drug-administration campaigns to prevent morbidity affecting at-risk groups in endemic regions. Although broadly successful, the use of albendazole and mebendazole achieved variable progress, with deficiencies against Trichuris trichiura and a predictable low efficacy against Strongyloides stercoralis. Novel drug combinations offer a potential solution, providing they can be delivered safely and maintain efficacy against all STH species. Here we present the protocol of a clinical trial to evaluate a fixed-dose combination (FDC) tablet containing albendazole and ivermectin that will be compared against albendazole against STH. Methods: An adaptive phase II/III randomized controlled trial will be undertaken in STH endemic sites in Ethiopia, Kenya and Mozambique to evaluate an oral FDC of 400 mg albendazole and either 9- or 18 mg ivermectin. FDC will be administered as a single dose or single doses over three-consecutive days and assessed against a single dose of 400 mg albendazole. In the phase II trial, 126 T. trichiura-infected children weighting 15 to 45 kg will be treated in a dose-escalation manner to determine safety objectives. In the phase III trial, 1097 participants aged 5 to 18 years old infected with T. trichiura, hookworm and S. stercoralis will be recruited to determine safety and efficacy. The trial will be open-label with blinded outcome assessors. Cure rate measured 21-days after-treatment in duplicate Kato-Katz is the primary efficacy outcome. Secondary objectives include efficacy evaluation by quantitative polymerase chain reaction (PCR) as an outcome measurement, description of pharmacokinetic parameters, palatability and acceptability evaluations, and monitoring of anthelmintic resistance. Conclusions: This trial with registrational goals seeks to evaluate an innovative fixed-dose combination of albendazole and ivermectin co-formulated tablets, with the goal of providing an anthelmintic regimen with improved efficacy and spectrum of coverage against STH. ClinicalTrials.gov registration: NCT05124691 (18/11/2021).Fil: Krolewiecki, Alejandro Javier. Universidad de Barcelona; España. Universidad Nacional de Salta. Sede Regional Orán. Instituto de Investigación de Enfermedades Tropicales; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Enbiale, Wendemagegn. Bahir Dar University; Etiopía. Amsterdam Institute for Infection and Immunity; Países BajosFil: Gandasegui, Javier. Universidad de Barcelona; EspañaFil: van Lieshout, Lisette. Leiden University; Países BajosFil: Kepha, Stella. Kenya Medical Research Institute; KeniaFil: Messa Junior, Augusto. Centro de Investigação em Saúde de Manhiça; MozambiqueFil: Bengtson, Michel. Leiden University. Leiden University Medical Center.; Países BajosFil: Gelaye, Woyneshet. Bahir Dar University; EtiopíaFil: Escola, Valdemiro. Centro de Investigação em Saúde de Manhiça; MozambiqueFil: Martinez Valladares, María. Universidad de León; España. Consejo Superior de Investigaciones Científicas; EspañaFil: Cambra Pellejà, María. Universidad de León; España. Consejo Superior de Investigaciones Científicas; EspañaFil: Algorta, Jaime. Liconsa Sa; EspañaFil: Martí Soler, Helena. Universidad de Barcelona; España. Consejo Superior de Investigaciones Científicas; EspañaFil: Fleitas, Pedro. Consejo Superior de Investigaciones Científicas; España. Universidad de Barcelona; EspañaFil: Ballester, Maria Rosa. Centro de Investigación Biomédica en Red de Salud Mental; España. Institut d’Investigació Biomèdica Sant Pau; EspañaFil: Doyle, Stephen R.. Wellcome Sanger Institute; Reino UnidoFil: Williams, Nana Aba. Universidad de Barcelona; España. Consejo Superior de Investigaciones Científicas; EspañaFil: Legarda, Almudena. Consejo Superior de Investigaciones Científicas; España. Universidad de Barcelona; EspañaFil: Mandomando, Inacio. Centro de Investigação Em Saúde de Manhiça; MozambiqueFil: Mwandawiro, Charles. Eastern and Southern Africa Centre of International Parasite Control; KeniaFil: Muñoz, José. Universidad de Barcelona; España. Consejo Superior de Investigaciones Científicas; EspañaBill & Melinda Gates Foundation2022-05info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/244741Krolewiecki, Alejandro Javier; Enbiale, Wendemagegn; Gandasegui, Javier; van Lieshout, Lisette; Kepha, Stella; et al.; An adaptive phase II/III safety and efficacy randomized controlled trial of single day or three-day fixed-dose albendazole-ivermectin co-formulation versus albendazole for the treatment of Trichuris trichiura and other STH infections. ALIVE trial protocol; Bill & Melinda Gates Foundation; Gates Open Research; 6; 5-2022; 1-132572-4754CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://gatesopenresearch.org/articles/6-62/v1info:eu-repo/semantics/altIdentifier/doi/10.12688/gatesopenres.13615.1info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:09:05Zoai:ri.conicet.gov.ar:11336/244741instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:09:05.937CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv	An adaptive phase II/III safety and efficacy randomized controlled trial of single day or three-day fixed-dose albendazole-ivermectin co-formulation versus albendazole for the treatment of Trichuris trichiura and other STH infections. ALIVE trial protocol
title	An adaptive phase II/III safety and efficacy randomized controlled trial of single day or three-day fixed-dose albendazole-ivermectin co-formulation versus albendazole for the treatment of Trichuris trichiura and other STH infections. ALIVE trial protocol
spellingShingle	An adaptive phase II/III safety and efficacy randomized controlled trial of single day or three-day fixed-dose albendazole-ivermectin co-formulation versus albendazole for the treatment of Trichuris trichiura and other STH infections. ALIVE trial protocol Krolewiecki, Alejandro Javier ANTIHELMINTICS STH TRICHURIS TRICHIURA HOOKWORM ALBENDAZOLE IVERMECTIN
title_short	An adaptive phase II/III safety and efficacy randomized controlled trial of single day or three-day fixed-dose albendazole-ivermectin co-formulation versus albendazole for the treatment of Trichuris trichiura and other STH infections. ALIVE trial protocol
title_full	An adaptive phase II/III safety and efficacy randomized controlled trial of single day or three-day fixed-dose albendazole-ivermectin co-formulation versus albendazole for the treatment of Trichuris trichiura and other STH infections. ALIVE trial protocol
title_fullStr	An adaptive phase II/III safety and efficacy randomized controlled trial of single day or three-day fixed-dose albendazole-ivermectin co-formulation versus albendazole for the treatment of Trichuris trichiura and other STH infections. ALIVE trial protocol
title_full_unstemmed	An adaptive phase II/III safety and efficacy randomized controlled trial of single day or three-day fixed-dose albendazole-ivermectin co-formulation versus albendazole for the treatment of Trichuris trichiura and other STH infections. ALIVE trial protocol
title_sort	An adaptive phase II/III safety and efficacy randomized controlled trial of single day or three-day fixed-dose albendazole-ivermectin co-formulation versus albendazole for the treatment of Trichuris trichiura and other STH infections. ALIVE trial protocol
dc.creator.none.fl_str_mv	Krolewiecki, Alejandro Javier Enbiale, Wendemagegn Gandasegui, Javier van Lieshout, Lisette Kepha, Stella Messa Junior, Augusto Bengtson, Michel Gelaye, Woyneshet Escola, Valdemiro Martinez Valladares, María Cambra Pellejà, María Algorta, Jaime Martí Soler, Helena Fleitas, Pedro Ballester, Maria Rosa Doyle, Stephen R. Williams, Nana Aba Legarda, Almudena Mandomando, Inacio Mwandawiro, Charles Muñoz, José
author	Krolewiecki, Alejandro Javier
author_facet	Krolewiecki, Alejandro Javier Enbiale, Wendemagegn Gandasegui, Javier van Lieshout, Lisette Kepha, Stella Messa Junior, Augusto Bengtson, Michel Gelaye, Woyneshet Escola, Valdemiro Martinez Valladares, María Cambra Pellejà, María Algorta, Jaime Martí Soler, Helena Fleitas, Pedro Ballester, Maria Rosa Doyle, Stephen R. Williams, Nana Aba Legarda, Almudena Mandomando, Inacio Mwandawiro, Charles Muñoz, José
author_role	author
author2	Enbiale, Wendemagegn Gandasegui, Javier van Lieshout, Lisette Kepha, Stella Messa Junior, Augusto Bengtson, Michel Gelaye, Woyneshet Escola, Valdemiro Martinez Valladares, María Cambra Pellejà, María Algorta, Jaime Martí Soler, Helena Fleitas, Pedro Ballester, Maria Rosa Doyle, Stephen R. Williams, Nana Aba Legarda, Almudena Mandomando, Inacio Mwandawiro, Charles Muñoz, José
author2_role	author author author author author author author author author author author author author author author author author author author author
dc.subject.none.fl_str_mv	ANTIHELMINTICS STH TRICHURIS TRICHIURA HOOKWORM ALBENDAZOLE IVERMECTIN
topic	ANTIHELMINTICS STH TRICHURIS TRICHIURA HOOKWORM ALBENDAZOLE IVERMECTIN
purl_subject.fl_str_mv	https://purl.org/becyt/ford/3.3 https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv	Background: Soil-transmitted helminths (STH) are targeted for control through mass drug-administration campaigns to prevent morbidity affecting at-risk groups in endemic regions. Although broadly successful, the use of albendazole and mebendazole achieved variable progress, with deficiencies against Trichuris trichiura and a predictable low efficacy against Strongyloides stercoralis. Novel drug combinations offer a potential solution, providing they can be delivered safely and maintain efficacy against all STH species. Here we present the protocol of a clinical trial to evaluate a fixed-dose combination (FDC) tablet containing albendazole and ivermectin that will be compared against albendazole against STH. Methods: An adaptive phase II/III randomized controlled trial will be undertaken in STH endemic sites in Ethiopia, Kenya and Mozambique to evaluate an oral FDC of 400 mg albendazole and either 9- or 18 mg ivermectin. FDC will be administered as a single dose or single doses over three-consecutive days and assessed against a single dose of 400 mg albendazole. In the phase II trial, 126 T. trichiura-infected children weighting 15 to 45 kg will be treated in a dose-escalation manner to determine safety objectives. In the phase III trial, 1097 participants aged 5 to 18 years old infected with T. trichiura, hookworm and S. stercoralis will be recruited to determine safety and efficacy. The trial will be open-label with blinded outcome assessors. Cure rate measured 21-days after-treatment in duplicate Kato-Katz is the primary efficacy outcome. Secondary objectives include efficacy evaluation by quantitative polymerase chain reaction (PCR) as an outcome measurement, description of pharmacokinetic parameters, palatability and acceptability evaluations, and monitoring of anthelmintic resistance. Conclusions: This trial with registrational goals seeks to evaluate an innovative fixed-dose combination of albendazole and ivermectin co-formulated tablets, with the goal of providing an anthelmintic regimen with improved efficacy and spectrum of coverage against STH. ClinicalTrials.gov registration: NCT05124691 (18/11/2021). Fil: Krolewiecki, Alejandro Javier. Universidad de Barcelona; España. Universidad Nacional de Salta. Sede Regional Orán. Instituto de Investigación de Enfermedades Tropicales; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Enbiale, Wendemagegn. Bahir Dar University; Etiopía. Amsterdam Institute for Infection and Immunity; Países Bajos Fil: Gandasegui, Javier. Universidad de Barcelona; España Fil: van Lieshout, Lisette. Leiden University; Países Bajos Fil: Kepha, Stella. Kenya Medical Research Institute; Kenia Fil: Messa Junior, Augusto. Centro de Investigação em Saúde de Manhiça; Mozambique Fil: Bengtson, Michel. Leiden University. Leiden University Medical Center.; Países Bajos Fil: Gelaye, Woyneshet. Bahir Dar University; Etiopía Fil: Escola, Valdemiro. Centro de Investigação em Saúde de Manhiça; Mozambique Fil: Martinez Valladares, María. Universidad de León; España. Consejo Superior de Investigaciones Científicas; España Fil: Cambra Pellejà, María. Universidad de León; España. Consejo Superior de Investigaciones Científicas; España Fil: Algorta, Jaime. Liconsa Sa; España Fil: Martí Soler, Helena. Universidad de Barcelona; España. Consejo Superior de Investigaciones Científicas; España Fil: Fleitas, Pedro. Consejo Superior de Investigaciones Científicas; España. Universidad de Barcelona; España Fil: Ballester, Maria Rosa. Centro de Investigación Biomédica en Red de Salud Mental; España. Institut d’Investigació Biomèdica Sant Pau; España Fil: Doyle, Stephen R.. Wellcome Sanger Institute; Reino Unido Fil: Williams, Nana Aba. Universidad de Barcelona; España. Consejo Superior de Investigaciones Científicas; España Fil: Legarda, Almudena. Consejo Superior de Investigaciones Científicas; España. Universidad de Barcelona; España Fil: Mandomando, Inacio. Centro de Investigação Em Saúde de Manhiça; Mozambique Fil: Mwandawiro, Charles. Eastern and Southern Africa Centre of International Parasite Control; Kenia Fil: Muñoz, José. Universidad de Barcelona; España. Consejo Superior de Investigaciones Científicas; España
description	Background: Soil-transmitted helminths (STH) are targeted for control through mass drug-administration campaigns to prevent morbidity affecting at-risk groups in endemic regions. Although broadly successful, the use of albendazole and mebendazole achieved variable progress, with deficiencies against Trichuris trichiura and a predictable low efficacy against Strongyloides stercoralis. Novel drug combinations offer a potential solution, providing they can be delivered safely and maintain efficacy against all STH species. Here we present the protocol of a clinical trial to evaluate a fixed-dose combination (FDC) tablet containing albendazole and ivermectin that will be compared against albendazole against STH. Methods: An adaptive phase II/III randomized controlled trial will be undertaken in STH endemic sites in Ethiopia, Kenya and Mozambique to evaluate an oral FDC of 400 mg albendazole and either 9- or 18 mg ivermectin. FDC will be administered as a single dose or single doses over three-consecutive days and assessed against a single dose of 400 mg albendazole. In the phase II trial, 126 T. trichiura-infected children weighting 15 to 45 kg will be treated in a dose-escalation manner to determine safety objectives. In the phase III trial, 1097 participants aged 5 to 18 years old infected with T. trichiura, hookworm and S. stercoralis will be recruited to determine safety and efficacy. The trial will be open-label with blinded outcome assessors. Cure rate measured 21-days after-treatment in duplicate Kato-Katz is the primary efficacy outcome. Secondary objectives include efficacy evaluation by quantitative polymerase chain reaction (PCR) as an outcome measurement, description of pharmacokinetic parameters, palatability and acceptability evaluations, and monitoring of anthelmintic resistance. Conclusions: This trial with registrational goals seeks to evaluate an innovative fixed-dose combination of albendazole and ivermectin co-formulated tablets, with the goal of providing an anthelmintic regimen with improved efficacy and spectrum of coverage against STH. ClinicalTrials.gov registration: NCT05124691 (18/11/2021).
publishDate	2022
dc.date.none.fl_str_mv	2022-05
dc.type.none.fl_str_mv	info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo
format	article
status_str	publishedVersion
dc.identifier.none.fl_str_mv	http://hdl.handle.net/11336/244741 Krolewiecki, Alejandro Javier; Enbiale, Wendemagegn; Gandasegui, Javier; van Lieshout, Lisette; Kepha, Stella; et al.; An adaptive phase II/III safety and efficacy randomized controlled trial of single day or three-day fixed-dose albendazole-ivermectin co-formulation versus albendazole for the treatment of Trichuris trichiura and other STH infections. ALIVE trial protocol; Bill & Melinda Gates Foundation; Gates Open Research; 6; 5-2022; 1-13 2572-4754 CONICET Digital CONICET
url	http://hdl.handle.net/11336/244741
identifier_str_mv	Krolewiecki, Alejandro Javier; Enbiale, Wendemagegn; Gandasegui, Javier; van Lieshout, Lisette; Kepha, Stella; et al.; An adaptive phase II/III safety and efficacy randomized controlled trial of single day or three-day fixed-dose albendazole-ivermectin co-formulation versus albendazole for the treatment of Trichuris trichiura and other STH infections. ALIVE trial protocol; Bill & Melinda Gates Foundation; Gates Open Research; 6; 5-2022; 1-13 2572-4754 CONICET Digital CONICET
dc.language.none.fl_str_mv	eng
language	eng
dc.relation.none.fl_str_mv	info:eu-repo/semantics/altIdentifier/url/https://gatesopenresearch.org/articles/6-62/v1 info:eu-repo/semantics/altIdentifier/doi/10.12688/gatesopenres.13615.1
dc.rights.none.fl_str_mv	info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv	openAccess
rights_invalid_str_mv	https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv	application/pdf application/pdf
dc.publisher.none.fl_str_mv	Bill & Melinda Gates Foundation
publisher.none.fl_str_mv	Bill & Melinda Gates Foundation
dc.source.none.fl_str_mv	reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str	CONICET Digital (CONICET)
collection	CONICET Digital (CONICET)
instname_str	Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv	CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv	dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_	1844613965655572480
score	13.069144

An adaptive phase II/III safety and efficacy randomized controlled trial of single day or three-day fixed-dose albendazole-ivermectin co-formulation versus albendazole for the trea...

Publicaciones similares